KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EPS (Weighted Average and Diluted) (2016 - 2025)

Jazz Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at $3.34 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $3.34 for Q4 2025, up 10.6% from a year ago — trailing twelve months through Dec 2025 was -$1.3 (down 114.94% YoY), and the annual figure for FY2025 was -$5.84, down 167.51%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $3.34 at Jazz Pharmaceuticals, down from $4.08 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for JAZZ hit a ceiling of $4.08 in Q3 2025 and a floor of -$11.74 in Q2 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $1.04 (2023), compared with a mean of $0.08.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 611.11% in 2022 and later skyrocketed 3366.67% in 2023.
  • Jazz Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.54 in 2021, then plummeted by 611.11% to -$3.84 in 2022, then soared by 137.24% to $1.43 in 2023, then skyrocketed by 111.19% to $3.02 in 2024, then increased by 10.6% to $3.34 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $3.34 (Q4 2025), $4.08 (Q3 2025), and -$11.74 (Q2 2025) per Business Quant data.